Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.